About Compass Therapeutics, Inc.
https://www.compasstherapeutics.comCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases.
CEO
Thomas J. Schuetz
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 73
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
D. Boral Capital
Buy
Guggenheim
Buy
HC Wainwright & Co.
Buy
Jefferies
Buy
Leerink Partners
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
TANG CAPITAL MANAGEMENT LLC
Shares:16.81M
Value:$101.54M
ORBIMED ADVISORS LLC
Shares:15.22M
Value:$91.93M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:14.1M
Value:$85.17M
Summary
Showing Top 3 of 130
About Compass Therapeutics, Inc.
https://www.compasstherapeutics.comCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $15.82M ▼ | $-14.26M ▲ | 0% | $-0.1 ▲ | $-14.24M ▲ |
| Q2-2025 | $0 | $21.07M ▲ | $-19.88M ▼ | 0% | $-0.14 ▼ | $-20.7M ▼ |
| Q1-2025 | $0 | $17.97M ▲ | $-16.63M ▼ | 0% | $-0.12 ▼ | $-17.6M ▼ |
| Q4-2024 | $0 | $16.57M ▲ | $-15.03M ▼ | 0% | $-0.11 ▼ | $-16.21M ▼ |
| Q3-2024 | $0 | $12.24M | $-10.48M | 0% | $-0.08 | $-11.77M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $219.9M ▲ | $231.26M ▲ | $21.65M ▼ | $209.61M ▲ |
| Q2-2025 | $100.95M ▼ | $116.7M ▼ | $23.49M ▲ | $93.21M ▼ |
| Q1-2025 | $112.64M ▼ | $131.45M ▼ | $21.17M ▲ | $110.28M ▼ |
| Q4-2024 | $126.72M ▼ | $140.4M ▼ | $15.17M ▲ | $125.23M ▼ |
| Q3-2024 | $135.4M | $149.15M | $10.75M | $138.4M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-14.26M ▲ | $-10.85M ▲ | $-95.16M ▼ | $129.36M ▲ | $23.36M ▲ | $0 ▲ |
| Q2-2025 | $-19.88M ▼ | $-11.83M ▲ | $-6.36M ▼ | $0 ▲ | $-18.19M ▼ | $-11.83M ▲ |
| Q1-2025 | $-16.63M ▼ | $-13.21M ▼ | $11.59M ▼ | $-815K ▼ | $-2.44M ▼ | $-13.23M ▼ |
| Q4-2024 | $-15.03M ▼ | $-9.16M ▲ | $15.37M ▼ | $-94K ▼ | $6.11M ▼ | $-9.16M ▲ |
| Q3-2024 | $-10.48M | $-11.05M | $29.02M | $-2K | $17.96M | $-11.1M |
CEO
Thomas J. Schuetz
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 73
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
D. Boral Capital
Buy
Guggenheim
Buy
HC Wainwright & Co.
Buy
Jefferies
Buy
Leerink Partners
Outperform
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
TANG CAPITAL MANAGEMENT LLC
Shares:16.81M
Value:$101.54M
ORBIMED ADVISORS LLC
Shares:15.22M
Value:$91.93M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:14.1M
Value:$85.17M
Summary
Showing Top 3 of 130